Logo
x

Search

Subscribe Now

Men

The US FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

The US FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

  • December 1, 2020
Bayer's Nubeqa (darolutamide) Receives the EC's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Bayer's Nubeqa (darolutamide) Receives the EC's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

  • March 31, 2020
Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Bayer's Nubeqa (darolutamide) Receives MHLW's Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

  • January 23, 2020
Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men

Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men

  • November 27, 2019
Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer

Myovant Sciences Reports Results of Relugolix in P-III HERO Study for Men with Advanced Prostate Cancer

  • November 20, 2019
Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castrate-Resistant Prostate Cancer in Men

Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castra...

  • August 8, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.